Competitive Landscape Analysis of Recent Cell and Gene Therapy Innovations

Competitive Landscape Analysis of Recent Cell and Gene Therapy Innovations

Emerging Chimeric Antigen Receptor (CAR) T-cell Therapy Platforms

RELEASE DATE
07-Jul-2020
REGION
Global
Research Code: D95F-01-00-00-00
SKU: HC03317-GL-TR_24576

$4,950.00

Special Price $4,207.50 save 15 %

In stock
SKU
HC03317-GL-TR_24576

$4,950.00

$4,207.50 save 15 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

This research identifies some the key developments across CAR-T cell therapies and provides insights across technological, IP, and investment landscapes. The study also provides an analysis of the competitive landscape while highlighting the key growth opportunities within the CAR-T cell therapy platform.

Table of Contents

1.1 Research Focus: Emerging Technologies Enabling chimeric antigen receptor (CAR) T-cell Therapies

1.2 Analysis Framework: Frost & Sullivan Core Value

1.3 Research Methodology: Five Steps Toward Success

1.4 Key Findings of Technology Breakthrough Driving Sepsis Diagnosis

2.1 Rising Pace of Cell and Gene Therapy Approvals

2.2 Regulatory and Ethical Perspectives on Gene Therapy

2.3 Rising Demand for Precision Medicine Strategies

2.4 Manufacturing Continues to be the Key Bottle Neck

2.5 II Generation Chimeric Antigen ReceptorS Likely to Dominate the Cell Therapy Landscape in the Future

2.6 CD-19 is the Most Common Target Antigen for Allogeneic CAR-T Therapies

3.1 Steady Increase in Patent Grants for CAR-T Cell Therapies

3.2 University of Pennsylvania and Novartis Lead the Patent Landscape for CAR-T Cell Therapies

3.3 China and the US Lead the Patent Landscape for CAR-T Cell Therapies

3.4 Snapshot of Key Patent Grants: Novartis

3.5 Snapshot of Key Patent Grants: Cellectis and BlueBird Bio

4.1 Key M&A Trends Across the Global Life Sciences Sector

4.2 Gene Therapy – Venture Capital Funding Assessment

4.3 Gene Therapy – Big Pharma In-licensing Deals Assessment

4.4 Strategic Insights: Cell Therapies and Gene Therapies, Viral Vector CMOs

5.1 Allogene Therapeutics

5.2 Precision BioSciences Inc.

5.3 CRISPR Therapeutics AG

5.4 Cellectis S.A.

5.5 Celyad

5.6 Bristol-Myers Squibb (BMS)

5.7 Gilead

5.8 Novartis

5.9 BlueBird Bio

5.10 Summary of the Scoring Methodology

5.11 Competitive Analysis of CAR-T Participants

6.1 Growth Opportunity: CAR-T for Solid tumors, 2020

6.2 Growth Opportunity: CAR-T for Solid tumors, 2020

Key Contacts

Key Contacts

Legal Disclaimer

Related Research
This research identifies some the key developments across CAR-T cell therapies and provides insights across technological, IP, and investment landscapes. The study also provides an analysis of the competitive landscape while highlighting the key growth opportunities within the CAR-T cell therapy platform.
More Information
No Index No
Podcast No
Author Vandana Iyer
Industries Healthcare
WIP Number D95F-01-00-00-00
Is Prebook No